DGAP-News: Nanostart subsidiary MagForce Nanotechnologies AG announces establishment of NanoTherm therapy treatment center at Charité-Universitätsmedizin Berlin
(firmenpresse) - DGAP-News: Nanostart AG / Key word(s): Miscellaneous
Nanostart subsidiary MagForce Nanotechnologies AG announces
establishment of NanoTherm therapy treatment center at
Charité-Universitätsmedizin Berlin
08.07.2011 / 11:44
---------------------------------------------------------------------
Nanostart subsidiary MagForce Nanotechnologies AG announces establishment
of NanoTherm therapy treatment center at Charité-Universitätsmedizin
Berlin
Frankfurt / Berlin - July 8, 2011 - Nanostart subsidiary MagForce
Nanotechnologies AG (FSE: MF6), a leading medical technology company
focusing on nanomedicine in oncology, announced that the
Charité-Universitätsmedizin Berlin published the establishment of its
NanoTherm therapy center for the treatment of recurrent brain tumors.
The principle of the therapy is the use of nanoparticles containing iron
oxide, which are injected into brain tumor in a procedure similar to a
biopsy. The treatment is carried out in a magnetic field applicator
(NanoActivator), a machine that produces an alternating magnetic field and
is very safe for humans. Through this high frequency magnetic field, the
nanoparticles begin to oscillate and heat is produced from directly within
the tumor tissue. Depending on the temperature reached and length of
treatment, the tumor cells are either directly destroyed or sensitized for
the accompanying chemotherapy or radiation. This novel therapy has the
potential to improve the survival for patients with recurrent glioblastoma,
an especially malignant type of brain tumor.
'I am pleased that we have accomplished this first step in making NanoTherm
therapy available to brain tumor patients,' said Dr. Peter Heinrich, CEO of
MagForce. 'There have been many challenges associated with introducing a
completely new therapeutic approach to the medical community; therefore,
the initial rollout has taken longer than expected. Our sales team is
active throughout Germany and currently in discussion with leading medical
institutions to establish additional treatment centers. We are also working
to make the therapy internationally available.'
Dr. Andreas Jordan, CSO and founder of MagForce added, 'We are pursuing the
further development of NanoTherm therapy for the treatment of prostate and
pancreatic carcinomas. NanoTherm therapy has enormous therapeutic potential
to treat a variety of solid tumors, and we are just at the beginning.'
Marco Beckmann, CEO of Nanostart AG, commented: 'Now that our subsidiary
MagForce's therapy is available at the Charité, this marks the start of the
long-awaited commercialization of this new type of cancer therapy based on
nanotechnology. We congratulate the MagForce team.'
Please read the press release of the Charitéhere:
http://www.charite.de/en/charite/press/press_reports/artikel/detail/charit
e_etabliert_nanothermR_therapie_bei_rueckfaellen_von_gehirntumoren/
About Nanostart:
Nanostart AG, headquartered in the German financial capital of Frankfurt,
is the world's leading nanotechnology investment company, with portfolio
companies spanning the globe from Silicon Valley to Singapore. The company
provides venture capital financing for nanotechnology companies in various
growth phases with a focus on innovation-driven industries of the future
such as cleantech, life sciences and IT/electronics. Through its subsidiary
and venture capital fund in Singapore, Nanostart is proud to be the
investment partner of the Singaporean government. For further information,
please visit www.nanostart.de.
About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is a leading medical technology company
focusing on nanomedicine in oncology. The company's proprietary procedure,
NanoTherm(R) therapy, enables the targeted treatment of solid tumors
through the intratumoral generation of heat via activation of magnetic
nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(TM) are
components of the therapy and have received EU-wide regulatory approval as
medical devices for the treatment of brain tumors. MagForce, NanoTherm,
NanoPlan and NanoActivator are trademarks of MagForce Nanotechnologies AG
in selected countries.For further information, please visit:
www.magforce.de.
About the Charité:
The Charitéis one of the largest university hospitals in Europe. Here,
3800 doctors and scientists heal, do research and teach at the top
international level. More than half of the German Nobel Prize winners in
medicine and physiology come from the Charité, among them Emil von Behring,
Robert Koch and Paul Ehrlich. The Charitéalso has an international
reputation for excellence in training. It extends over four campuses with
more than 100 clinics and institutes bundled under 17 CharitéCenters. With
more than 13,000 employees, the Charitégenerates about 1.2 billion euros
in sales per year and is one of the largest employers in Berlin. For
further information, please visit: www.charite.de.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the 'Entry Standard' segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice nor
the information contained within is intended for direct or indirect
distribution within Canada, Australia or Japan.
Media contact:
Nanostart AG
Head of Corporate Communications
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
e-mail: presse(at)nanostart.de
End of Corporate News
---------------------------------------------------------------------
08.07.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
131382 08.07.2011
Datum: 08.07.2011 - 11:44 Uhr
Sprache: Deutsch
News-ID 34571
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 206 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Nanostart subsidiary MagForce Nanotechnologies AG announces establishment of NanoTherm therapy treatment center at Charité-Universitätsmedizin Berlin"
steht unter der journalistisch-redaktionellen Verantwortung von
Nanostart AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
